Feasibility and potential role of ferumoxytol-enhanced neuroimaging in HIV-associated neurocognitive disorder

Beau K. Nakamoto, Cecilia M. Shikuma, Debra Ogata-Arakaki, Tracie Umaki, Edward A. Neuwelt, Bruce T. Shiramizu, Dominic C. Chow, Nisha I. Parikh, Kalpana J. Kallianpur, Bronwyn E. Hamilton

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

We assessed ferumoxytol-enhanced brain MRI to identify monocyte/macrophage accumulation in HIV-associated neurocognitive disorder (HAND). Four HIV-infected subjects with undetectable HIV RNA levels on antiretroviral therapy, HIV DNA level in CD14+ cells ≥10 copies/106 cells, and cognitive impairment underwent ferumoxytol-enhanced brain MRI. On post-ferumoxytol susceptibility-weighted images, all HIV-infected subjects demonstrated a diffuse "tram track" appearance in the perivascular regions of cortical and deep white matter vessels suggesting ferumoxytol uptake in monocytes/ macrophages. This finding was not present in an HIV-seronegative control. While ferumoxytol may have potential as an imaging biomarker for monocyte/macrophage accumulation in patients with HAND, future study is needed.

Original languageEnglish (US)
Pages (from-to)601-605
Number of pages5
JournalJournal of neurovirology
Volume19
Issue number6
DOIs
StatePublished - Dec 2013

Keywords

  • Ferumoxytol
  • HIV
  • HIV dementia
  • MRI

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Virology

Fingerprint Dive into the research topics of 'Feasibility and potential role of ferumoxytol-enhanced neuroimaging in HIV-associated neurocognitive disorder'. Together they form a unique fingerprint.

Cite this